Bioresorbable scaffolds in the treatment of coronary artery disease

Medical Devices: Evidence and Research

Volumn 6, Issue 1, 2013, Pages 37-48

  Zhang, Yaojun ^a,b   Bourantas, Christos V ^a   Farooq, Vasim ^a   Muramatsu, Takashi ^a   Diletti, Roberto ^a   Onuma, Yoshinobu ^a   Garcia Garcia, Hector M ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Biodegradable; Bioresorbable scaffold; Coronary artery disease; Design; Drug eluting stent; Mechanism

Indexed keywords

BIODEGRADABLE; BIORESORBABLE SCAFFOLDS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; ENDOVASCULAR DEVICES; IN-STENT RESTENOSIS; PERCUTANEOUS CORONARY INTERVENTION; PHYSIOLOGIC FUNCTION;

ARTIFICIAL ORGANS; DESIGN; MECHANISMS; RESTORATION; SCAFFOLDS; STENTS;

DISEASES;

BIOABSORBABLE SCAFFOLD; PACLITAXEL; RAPAMYCIN; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

CARDIOVASCULAR STENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE SAFETY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; HUMAN; INTERMETHOD COMPARISON; MAGNESIUM METALLIC STENT; MATERIAL COATING; MOLECULAR WEIGHT; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PHYSICAL CHEMISTRY; PROCESS DEVELOPMENT; REVIEW; VASCULAR PATENCY;

EID: 84875116951     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/MDER.S22547     Document Type: Review

References (67)

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;1(8058):263.
2. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301(2):61-68.
3. Gruentzig AR, King SB 3rd, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med. 1987;316(18):1127-1132.
4. Nobuyoshi M, Kimura T, Nosaka H, etal. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol. 1988;12(3):616-623.
5. Ormiston JA, Stewart FM, Roche AH, Webber BJ, Whitlock RM, Webster MW. Late regression of the dilated site after coronary angioplasty: a 5-year quantitative angiographic study. Circulation. 1997;96(2):468-474.
6. Fischman DL, Leon MB, Baim DS, etal. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331(8):496-501.
7. Mintz GS, Popma JJ, Pichard AD, etal. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94(1):35-43.
8. Moses JW, Leon MB, Popma JJ, etal. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323.
9. Serruys PW, de Jaegere P, Kiemeneij F, etal. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489-495.
10. Stone GW, Ellis SG, Cox DA, etal. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350(3):221-231.
11. Farooq V, Gogas BD, Serruys PW. Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv. 2011;4(2):195-205.
12. Serruys PW, Silber S, Garg S, etal. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2): 136-146.
13. Stone GW, Moses JW, Ellis SG, etal. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med. 2007; 356(10):998-1008.
14. Windecker S, Remondino A, Eberli FR, etal. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353(7):653-662.
15. Windecker S, Serruys PW, Wandel S, etal. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163-1173.
16. Zhang Y, Farooq V, Garcia-Garcia HM, etal. Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients. Euro Intervention. 2012;8(7):855-865.
17. Baber U, Mehran R, Sharma SK, etal. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58(15):1569-1577.
18. McFadden EP, Stabile E, Regar E, etal. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519-1521.
19. Serruys PW, Ormiston JA, Onuma Y, etal. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667): 897-910.
20. Stefanini GG, Kalesan B, Serruys PW, etal. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378(9807):1940-1948.
21. Bourantas CV, Onuma Y, Farooq V, Zhang Y, Garcia-Garcia HM, Serruys PW. Bioresorbable scaffolds: current knowledge, potentialities and limitations experienced during their first clinical applications. Int J Cardiol. Epub June 28, 2012.
22. Bourantas CV, Zhang Y, Farooq V, Garcia-Garcia HM, Onuma Y, Serruys PW. Bioresorbable scaffolds: current evidence and ongoing clinical trials. Curr Cardiol Rep. 2012;14(5):626-634.
23. Finn AV, Joner M, Nakazawa G, etal. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115(18):2435-2441.
24. Kotani J, Awata M, Nanto S, etal. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47(10):2108-2111.
25. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade. Eur Heart J. 2012;33(1):16b-25b.
26. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization. Circulation. 2011;123(7):779-797.
27. van der Giessen WJ, Slager CJ, van Beusekom HM, etal. Development of a polymer endovascular prosthesis and its implantation in porcine arteries. J Interv Cardiol. 1992;5(3):175-185.
28. van der Giessen WJ, Lincoff AM, Schwartz RS, etal. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 1996;94(7):1690-1697.
29. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 1997;29(4):808-816.
30. Yamawaki T, Shimokawa H, Kozai T, etal. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol. 1998;32(3):780-786.
31. Erbel R, Di Mario C, Bartunek J, etal. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet. 2007;369(9576):1869-1875.
32. Onuma Y, Serruys PW, Perkins LE, etal. Intracoronary optical coherence tomography and histology at 1month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122(22):2288-2300.
33. Ormiston JA, Serruys PW, Regar E, etal. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371(9616):899-907.
34. English JP, PDE. Polyglycolide and Polylactide. In: Wiseman DM, Kost J, Domb AJ, editors. Handbook of Biodegradable Polymers. Boca Raton, FL: CRC Press; 1998.
35. Kronenthal R. Biodegradable Polymers in Medicine and Surgery. In: Kronenthal R, Oser Z, Martin E, editors. Polymers in Medicine and Surgery. New York, NY: Plenum Press; 1975:119-137.
36. Garg S, Serruys P. Biodegradable stents and non-biodegradable stents. Minerva Cardioangiol. 2009;57(5):537-565.
37. Ormiston JA, Serruys PW. Bioabsorbable coronary stents. Circ Cardiovasc Interv. 2009;2(3):255-260.
38. Waksman R. Lessons learnt from preclinical studies of magnesium scaffolds (Biotronik's DREAMS program). EuroPCR; Mar 2012; Rotterdam, The Netherlands.
39. Tamai H, Igaki K, Kyo E, etal. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102(4):399-404.
40. Nishio S, Kosuga K, Igaki K, etal. Long-term (.10 years) clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai stents. Circulation. 2012;125(19):2343-2353.
41. Onuma Y, Garg S, Okamura T, etal. Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr Hideo Tamai. Euro Intervention. 2009;5 Suppl F:F109-F111.
42. Onuma Y, Serruys PW, Perkins LE, etal. Intracoronary optical coherence tomography and histology at 1month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation. 2010;122(22):2288-2300.
43. Serruys PW, Ormiston JA, Onuma Y, etal. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373(9667): 897-910.
44. Tanimoto S, Bruining N, van Domburg RT, etal. Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology. J Am Coll Cardiol. 2008;52(20):1616-1620.
45. Tanimoto S, Serruys PW, Thuesen L, etal. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv. 2007;70(4):515-523.
46. Diletti R, Onuma Y, Farooq V, etal. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J Am Coll Cardiol. 2011;58(3):258-264.
47. Serruys PW, Onuma Y, Dudek D, etal. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58(15):1578-1588.
48. Ormiston JA, Serruys PW, Onuma Y, etal. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv. 2012;5(5):620-632.
49. Serruys PW, Onuma Y. Vascular reparative therapy-a dream coming true? EuroPCR; May 16, 2012; Rotterdam, The Netherlands.
50. Farooq V, Gomez-Lara J, Brugaletta S, etal. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. Catheter Cardiovasc Interv. 2012;79(6):880-888.
51. Ghimire G, Spiro J, Kharbanda R, etal. Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. Euro Intervention. 2009;4(4):481-484.
52. Waksman R. PROGRESS was made toward DREAM: magnesium Stent. EuroPCR; May 17, 2012; Rotterdam, The Netherlands.
53. Pollman MJ. Engineering a bioresorbable stent: REVA programme update. Euro Intervention. 2009;5 Suppl F:F54-F57.
54. Strandberg E, Zeltinger J, Schulz DG, Kaluza GL. Late positive remodeling and late lumen gain contribute to vascular restoration by a non-drug eluting bioresorbable scaffold: a four-year intravascular ultrasound study in normal porcine coronary arteries. Circ Cardiovasc Interv. 2012;5(1):39-46.
55. Grube E. The Boston scientific and REVA technology. EuroPCR; May 22, 2009; Barcelona, Spain.
56. Yan J, Bhat VD. Elixir Medical's bioresorbable drug eluting stent (BDES) programme: an overview. Euro Intervention. 2009; 5 Suppl F:F80-F82.
57. Verheye S. DESolve first in man study-preliminary results. EuroPCR; Mar 2012; Rotterdam, The Netherlands.
58. Verheye S. DESolve myolimus eluting bioresorbable coronary scaffold first in man trial-imaging and clinical results at 6months. EuroPCR; May 16, 2012; Rotterdam, The Netherlands.
59. Jabara R, Chronos N, Robinson K. Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv. 2008;72(2):186-194.
60. Jabara R, Pendyala L, Geva S, Chen J, Chronos N, Robinson K. Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. Euro Intervention. 2009;5 Suppl F:F58-F64.
61. Jabara R. Poly-anhydride based on salicylic acid and adipic acid anhydride. EuroPCR; May 22, 2009; Barcelona, Spain.
62. Lafont A, Durand E. ART: concept of a bioresorbable stent without drug elution. Euro Intervention. 2009;5 Suppl F:F83-F87.
63. Lafont A. ART bioresorbable scaffold dedicated for vascular scaffolding. EuroPCR; May 17, 2012.
64. cvPIPELINE [database on the Internet]. Santa Barbara, CA: MarketMonitors Inc. Available from: http://www.cvpipeline.com. Accessed September 20, 2012.
65. Han Y, Zhang L, Yang L, etal. A new generation biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study. Euro Intervention. 2012;8(7):815-822.
66. Shen L, Wand Qi-bing, Wu Yi-zhe, etal. Preliminary evaluation of fully bioabsorbable PLLA sirolimus eluting stents in a porcine model. Chin J Intervent Cardiol. 2009;19(6):301-305.
67. Cottone RJ, Thatcher GL, Parker SP, etal. OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings. Euro Intervention. 2009;5 Suppl F:F65-F71.